At the news
? BULLISHIMPACT 7/10 6-K filed Mar 26, 2026 at 07:30 ET
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's ProlivRx system for treatment-resistant major depressive disorder. This brings BrainsWay's total investment in Neurolief to $11 million, with potential for an additional $5 million equity investment and a call option to acquire Neurolief outright.
- BrainsWay invested an additional $6 million in Neurolief via a convertible loan, triggered by FDA PMA approval of ProlivRx for MDD.
- Total investment by BrainsWay in Neurolief now stands at $11 million.
- Potential for an additional $5 million equity investment if Neurolief hits a revenue-based target.
- BrainsWay holds a call option to acquire all of Neurolief at a price based on enterprise value or revenue multiple.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access